LJPC La Jolla Pharmaceutical Co

Price (delayed)

$4.71

Market cap

$129.28M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.59

Enterprise value

$91.1M

Highlights
The revenue has soared by 128% YoY and by 79% from the previous quarter
The debt has plunged by 98% YoY and by 9% from the previous quarter
LJPC's quick ratio has soared by 66% since the previous quarter but it is down by 28% year-on-year
La Jolla Pharmaceutical's equity has increased by 18% from the previous quarter but it has decreased by 17% YoY
LJPC's gross margin is down by 14% year-on-year

Key stats

What are the main financial stats of LJPC
Market
Shares outstanding
27.45M
Market cap
$129.28M
Enterprise value
$91.1M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.52
Earnings
Revenue
$59.97M
EBIT
-$6.14M
EBITDA
-$2.65M
Free cash flow
-$6.29M
Per share
EPS
-$0.59
Free cash flow per share
-$0.23
Book value per share
-$2.64
Revenue per share
$2.19
TBVPS
$2
Balance sheet
Total assets
$89.59M
Total liabilities
$161.91M
Debt
$490,000
Equity
-$72.32M
Working capital
$42.56M
Liquidity
Debt to equity
-0.01
Current ratio
4.63
Quick ratio
3.66
Net debt/EBITDA
14.39
Margins
EBITDA margin
-4.4%
Gross margin
77.6%
Net margin
-27.4%
Operating margin
-13.1%
Efficiency
Return on assets
-18.8%
Return on equity
N/A
Return on invested capital
-44.5%
Return on capital employed
-7.9%
Return on sales
-10.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LJPC stock price

How has the La Jolla Pharmaceutical stock price performed over time
Intraday
-3.88%
1 week
-8.54%
1 month
25.27%
1 year
-14.83%
YTD
21.39%
QTD
11.08%

Financial performance

How have La Jolla Pharmaceutical's revenue and profit performed over time
Revenue
$59.97M
Gross profit
$46.53M
Operating income
-$7.89M
Net income
-$16.41M
Gross margin
77.6%
Net margin
-27.4%
The revenue has soared by 128% YoY and by 79% from the previous quarter
LJPC's gross profit has soared by 97% YoY and by 82% from the previous quarter
LJPC's operating margin has soared by 96% YoY and by 88% QoQ
The net margin has soared by 92% YoY and by 77% from the previous quarter

Growth

What is La Jolla Pharmaceutical's growth rate over time

Valuation

What is La Jolla Pharmaceutical stock price valuation
P/E
N/A
P/B
N/A
P/S
2.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.52
La Jolla Pharmaceutical's EPS has soared by 83% YoY and by 59% from the previous quarter
La Jolla Pharmaceutical's equity has increased by 18% from the previous quarter but it has decreased by 17% YoY
The revenue has soared by 128% YoY and by 79% from the previous quarter
The stock's P/S is 100% below its 5-year quarterly average of 949.0 and 35% below its last 4 quarters average of 3.3

Efficiency

How efficient is La Jolla Pharmaceutical business performance
La Jolla Pharmaceutical's ROS has soared by 97% YoY and by 88% from the previous quarter
La Jolla Pharmaceutical's return on invested capital has surged by 74% YoY and by 62% QoQ
The return on assets has surged by 71% year-on-year and by 55% since the previous quarter

Dividends

What is LJPC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LJPC.

Financial health

How did La Jolla Pharmaceutical financials performed over time
The total assets is 45% less than the total liabilities
LJPC's quick ratio has soared by 66% since the previous quarter but it is down by 28% year-on-year
The company's current ratio has surged by 57% QoQ but it fell by 14% YoY
The debt is 101% more than the equity
The debt has plunged by 98% YoY and by 9% from the previous quarter
La Jolla Pharmaceutical's debt to equity has surged by 98% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.